Oxford Nanopore Technologies Ltd is developing a disruptive, proprietary technology platform for the direct, electronic analysis of single molecules. The technology is adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule. Consequently, the platform has a broad range of potential applications, including scientific research, personalised medicine, crop science and security/defence.
RNA
GeneFluidics, Inc. develops electrochemical sensor platform for molecular analysis. Its solutions perform bioassays with sensitivity to picogram/ml concentrations for immunoassays and femtomolar concentrations for genetic assays.
U.S. Genomics has pioneered commercial applications of single molecule DNA, RNA and protein analysis. The company's innovative technologies which include proprietary technologies for extraction of high grade DNA from complex samples, tagging, microfluidics and genomic mapping, address high value unmet needs in bio-security, human diagnostics, and food and drug contaminant monitoring.
ExQor's patented bio-nanotransport platform enables delivery of many different types of drugs throughout the body, including the brain. Uniquely and unlike almost all other nano-particles, ExQor's could also become a powerful new therapeutic in its own right.
ExQor's multiple patents cover Clathrin, a vitally essential protein responsible for transporting a very broad variety of substances—from cholesterol to neurotransmitters—to the interior of cells. Clathrin is also implicated in viral diseases, like HIV.